Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Jun 2024
Second-gen ALK inhibitor induces high response rate, associated with impressive survival
Read Full NewsA novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.
Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.
Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.
Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.
A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.
People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.
Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.
1.
In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?
2.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
3.
Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants
4.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
5.
Less Mental Decline With Darolutamide vs Enzalutamide in PC
1.
Innate Lymphoid Cells in Tumor Biology
2.
Modern Applications in Oncology in the Digital Era
3.
Omentum Cancer: Causes, Symptoms, and Treatment Options
4.
Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data
5.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Should We Use DARA Up Front As First-Line Therapy in MM?
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge